MedTrace Logo

Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles

NCT02122536 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2014-04-24

No results posted yet for this study

Summary

The aim of this prospective, randomized, double-blind, intraindividual split face study will be to compare onabotulinumtoxinA to incobotulinumtoxinA for the correction of facial wrinkles using a 1:1 dose ratio.

Conditions

  • Facial Wrinkles

Interventions

DRUG

Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects

Subjects were randomized to which side of the face would be treated with Xeomin.

DRUG

Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects

Subjects were randomized to which side of the upper face would be treated with Botox

Sponsors & Collaborators

  • YMD Eye and Face

    lead OTHER

Principal Investigators

  • Ruth H Yeilding, MD · YMD Eye & Face

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02122536 on ClinicalTrials.gov